These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 29131038)

  • 21. Treatment Update of Autoimmune Blistering Diseases.
    Kridin K; Ahn C; Huang WC; Ansari A; Sami N
    Dermatol Clin; 2019 Apr; 37(2):215-228. PubMed ID: 30850044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IgM Deficiency in Autoimmune Blistering Mucocutaneous Diseases Following Various Treatments: Long Term Follow-Up and Relevant Observations.
    Ahmed AR; Aksoy M
    Front Immunol; 2021; 12():727520. PubMed ID: 34646266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of refractory blistering autoimmune diseases with mycophenolic acid.
    Marzano AV; Dassoni F; Caputo R
    J Dermatolog Treat; 2006; 17(6):370-6. PubMed ID: 17853312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open-label, single-arm, phase 1/2 study on 10 Japanese patients.
    Kurihara Y; Yamagami J; Funakoshi T; Ishii M; Miyamoto J; Fujio Y; Kakuta R; Tanikawa A; Aoyama Y; Iwatsuki K; Ishii N; Hashimoto T; Nishie W; Shimizu H; Kouyama K; Amagai M
    J Dermatol; 2019 Feb; 46(2):124-130. PubMed ID: 30585649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Management of bullous pemphigoid].
    Göbel M; Eming R
    Hautarzt; 2019 Apr; 70(4):236-242. PubMed ID: 30874841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New and emerging therapies in the treatment of blistering diseases.
    Korman NJ
    Dermatol Clin; 2000 Jan; 18(1):127-37, ix-x. PubMed ID: 10626118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication.
    Kolesnik M; Becker E; Reinhold D; Ambach A; Heim MU; Gollnick H; Bonnekoh B
    J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):771-80. PubMed ID: 23651052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
    Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L
    Front Immunol; 2020; 11():611549. PubMed ID: 33584689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
    Russo R; Cozzani E; Gasparini G; Parodi A
    Dermatol Ther; 2020 Jan; 33(1):e13190. PubMed ID: 31863534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical effect of omalizumab as an adjuvant treatment to rituximab in patient with refractory bullous pemphigoid.
    Kwon IJ; Kim T; Yoo DS; Min S; Kim SC; Kim JH
    J Dermatol; 2023 May; 50(5):705-709. PubMed ID: 36514846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab in Subepidermal Blistering Diseases.
    Tan WH; Sim J; Sultana R; Lee HY
    Dermatology; 2023; 239(1):5-11. PubMed ID: 36302346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autoimmune bullous dermatoses in the elderly: diagnosis and management.
    Mutasim DF
    Drugs Aging; 2003; 20(9):663-81. PubMed ID: 12831291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Autoimmune blistering skin diseases: diagnostic and therapeutic approach].
    Hammers CM; Schmidt E; Zillikens D
    Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1473-7. PubMed ID: 24983196
    [No Abstract]   [Full Text] [Related]  

  • 34. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
    Atzori L; Deidda S; Aste N
    G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A survey of bullous diseases in a Turkish university hospital: clinicoepidemiological characteristics and follow-up.
    Kutlubay Z; Sevim Keçici A; Çelik U; Mat MC
    Turk J Med Sci; 2021 Feb; 51(1):124-133. PubMed ID: 32892539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments.
    Bilgiç Temel A; Bassorgun CI; Akman-Karakaş A; Alpsoy E; Uzun S
    Case Rep Dermatol; 2017; 9(1):38-44. PubMed ID: 28413387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dermatologic uses of omalizumabtitle.
    Chia JC; Mydlarski PR
    J Dermatolog Treat; 2017 Jun; 28(4):332-337. PubMed ID: 27759482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mycophenolate mofetil for the management of autoimmune bullous diseases.
    Eskin-Schwartz M; David M; Mimouni D
    Immunol Allergy Clin North Am; 2012 May; 32(2):309-15, vii. PubMed ID: 22560143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders.
    Jolles S
    Clin Exp Dermatol; 2001 Mar; 26(2):127-31. PubMed ID: 11298100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoimmune bullous diseases in childhood.
    Sansaricq F; Stein SL; Petronic-Rosic V
    Clin Dermatol; 2012; 30(1):114-27. PubMed ID: 22137235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.